Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000631
Chunk: 24

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 24
---
 such shares of Series B Preferred Stock are converted to Common Stock pursuant to the terms of the Series B Certificate of Designation, subject to certain beneficial ownership limitations.

<div align='center'>18</div>

TABLE OF CONTENTS

The information set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Series B Preferred Stock and Private Placement Common Shares in connection with the Private Placement, and the issuance of Private Placement Conversion Shares upon conversion of the Series B Preferred Stock. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 25,725,306 shares of Common Stock outstanding as of November 22, 2024, and, for each Selling Stockholder, assumes the conversion of only the Series B Preferred Stock owned by such Selling Stockholder but not the Series B Preferred Stock owned by any other Selling Stockholder. The numbers of shares of Common Stock beneficially owned before and after the offering presented in the table below do not give effect to the Series B Beneficial Ownership Limitation, but do give effect to the Series A Beneficial Ownership Limitation.

| Name of Selling Stockholders(1)                                           |     |       Common 
        Stock 
 Beneficially 
        Owned 
       Before 
  Offering(2) |     |      Common 
  Stock that 
         May 
  Be Offered 
 Pursuant to 
  Prospectus |     | Common Stock 
 Beneficially 
  Owned After 
  Offering(2) |     |            |
|                                                                           |     |              |     |             |     |       Number |     | Percentage 
 (%)        |
| Entities affiliated with Timothy A. Springer, Ph.D.(3)                    |     |    9,481,816 |     |   2,359,500 |     |    7,122,316 |     | 27.5%      |
| Schooner Century Fund LLC(4)                                              |     |    1,608,709 |     |     737,500 |     |      871,209 |     | 3.3%       |
| Fidelity Growth Company Commingled Pool(5)                                |     |      461,147 |     |     461,147 |     |            — |     | —          |
| Fidelity Select Portfolios: Biotechnology Portfolio(6)                    |     |      884,159 |     |     375,000 |     |